Metoprolol blunts the time-dependent progression of infarct size by Lobo-González, Manuel et al.
Vol.:(0123456789) 
Basic Research in Cardiology (2020) 115:55 
https://doi.org/10.1007/s00395-020-0812-4
ORIGINAL CONTRIBUTION
Metoprolol blunts the time‑dependent progression of infarct size
Manuel Lobo‑Gonzalez1,2,3 · Carlos Galán‑Arriola1,3 · Xavier Rossello1,3,4 · Maribel González‐Del‐Hoyo1,5 · 
Jean Paul Vilchez1,6 · María I. Higuero‑Verdejo1,3 · Jose M. García‑Ruiz1,3,7 · Gonzalo J. López‑Martín1 · 
Javier Sánchez‑González1,8 · Eduardo Oliver1,3 · Gonzalo Pizarro1,3,6 · Valentin Fuster1,9 · Borja Ibanez1,2,3 
Received: 18 May 2020 / Accepted: 20 July 2020 / Published online: 3 August 2020 
© The Author(s) 2020
Abstract
Early metoprolol administration protects against myocardial ischemia–reperfusion injury, but its effect on infarct size pro-
gression (ischemic injury) is unknown. Eight groups of pigs (total n = 122) underwent coronary artery occlusion of varying 
duration (20, 25, 30, 35, 40, 45, 50, or 60 min) followed by reperfusion. In each group, pigs were randomized to i.v. meto-
prolol (0.75 mg/kg) or vehicle (saline) 20 min after ischemia onset. The primary outcome measure was infarct size (IS) on 
day7 cardiac magnetic resonance (CMR) normalized to area at risk (AAR, measured by perfusion computed tomography 
[CT] during ischemia). Metoprolol treatment reduced overall mortality (10% vs 26%, p = 0.03) and the incidence and num-
ber of primary ventricular fibrillations during infarct induction. In controls, IS after 20-min ischemia was ≈ 5% of the area 
AAR. Thereafter, IS progressed exponentially, occupying almost all the AAR after 35 min of ischemia. Metoprolol injection 
significantly reduced the slope of IS progression (p = 0.004 for final IS). Head-to-head comparison (metoprolol treated vs 
vehicle treated) showed statistically significant reductions in IS at 30, 35, 40, and 50-min reperfusion. At 60-min reperfu-
sion, IS was 100% of AAR in both groups. Despite more prolonged ischemia, metoprolol-treated pigs reperfused at 50 min 
had smaller infarcts than control pigs undergoing ischemia for 40 or 45 min and similar-sized infarcts to those undergoing 
35-min ischemia. Day-45 LVEF was higher in metoprolol-treated vs vehicle-treated pigs (41.6% vs 36.5%, p = 0.008). In 
summary, metoprolol administration early during ischemia attenuates IS progression and reduces the incidence of primary 
ventricular fibrillation. These data identify metoprolol as an intervention ideally suited to the treatment of STEMI patients 
identified early in the course of infarction and requiring long transport times before primary angioplasty.
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Introduction
Despite major improvements in reperfusion strategies and 
coadjuvant therapies, myocardial infarction (MI) remains 
a leading cause of mortality and morbidity worldwide [21, 
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30]. Infarct size (IS) is a major determinant of prognosis 
in MI survivors; therefore, interventions able to limit it are 
needed. Since the extent of irreversible injury progresses 
in a time-dependent manner, early blood flow restoration 
(reperfusion) is associated with lower IS, and this translates 
into better long-term outcomes [3, 33]. This notion is the 
basis of the widely applied “time is muscle” principle [18]. 
If provided early, the best reperfusion strategy for patients 
presenting with a ST-elevation MI (STEMI) is primary 
percutaneous coronary intervention (PPCI). PPCI stops 
ischemic injury progression immediately and performs bet-
ter than fibrinolysis in achieving adequate tissue perfusion 
and limiting microvascular injury. Unfortunately, PPCI is 
often not an immediate option, and reperfusion is delayed 
during patient transfer to a PCI facility. Current guidelines 
recommend PPCI if the anticipated time from STEMI diag-
nosis to wire crossing is ≤ 120 min [21]. If a longer transfer 
time is predicted, the recommended reperfusion strategy 
is systemic fibrinolysis. However, fibrinolysis results in 
complete reperfusion in only ~ 50% of treated patients and 
exposes patients to potentially serious bleeding events, such 
as intracranial hemorrhage [21]. Interventions to delay the 
progression of ischemic damage could theoretically extend 
the 120 min window for selecting PPCI over fibrinolysis, 
allowing more patients to benefit from the best reperfusion 
strategy.
Intravenous (i.v.) administration of metoprolol during 
ongoing ischemia is associated with smaller infarcts, both 
in experimental models [6, 7, 23] and in a recent clinical 
trial [22, 27]. In experimental and clinical settings, the car-
dioprotective effect of i.v. metoprolol is dependent on the 
timing of administration; when injected very close to rep-
erfusion, metoprolol has no infarct-limiting effect [7]. This 
timing-dependent cardioprotective effect might explain the 
neutral effects reported in another recent clinical trial [29]. 
The fact that i.v. metoprolol reduced IS only when injected 
long before reperfusion suggests that it might slow the rate 
of ischemic death (i.e. infarction progression).
To address this question, we studied the trajectories of IS 
progression in the presence or absence of i.v. metoprolol in 
a pig model of STEMI. To mimic the clinical scenario, i.v. 
metoprolol or vehicle was injected 20 min after coronary 
artery occlusion, and pigs were reperfused at different times, 
from immediately after injection to 40 min later (i.e. 60 min 
after ischemia onset). All pigs underwent cardiac magnetic 
resonance (CMR) imaging examinations at 7 and 45 days 
after STEMI induction.
Methods
The study was conducted at Centro Nacional de Investiga-
ciones Cardiovasculares (CNIC) facilities and approved by 
Institutional and Regional Animal Research Committees. All 
animal procedures conformed to EU Directive 2010/63EU 
and Recommendation 2007/526/EC regarding the protec-
tion of animals used for experimental and other scientific 
purposes.
Fig. 1  Study design. Large white pigs (30–35  kg) were allocated 
to eight periods of ischemia by left anterior descending occlusion 
for 20 (n = 10), 25 (n = 10), 30 (n = 10), 35 (n = 10), 40 (n = 24), 45 
(n = 24), 50 (n = 24), or 60 (n = 10) min, followed by reperfusion. 
Animals were 1:1 randomized to receive either intravenous metopro-
lol (0.75 mg/kg) or saline 20 min after ischemia onset. MDCT scans 
were performed during the course of ischemia. Cardiac magnetic res-
onance scans were performed 7 days after reperfusion, and 45 days 
after reperfusion
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Study design
The study design is presented in Fig.  1. The study was 
performed in 3-month-old male large white pigs weigh-
ing 30–35 kg following state-of-the art methodologies [1, 
17, 25]. Eight groups of pigs were scheduled to undergo 
ischemia for differing durations (20 min, 25 min, 30 min, 
35 min, 40 min, 45 min, 50 min, or 60 min). Ischemia was 
induced by inflating an angioplasty balloon in the mid-por-
tion of the left anterior descending (LAD) coronary artery. 
At the end of the pre-specified ischemia duration, animals 
were reperfused (balloon deflation) and recovered from 
anesthesia. All pigs underwent contrast-enhanced multi-
detector computed tomography (MDCT) during coronary 
occlusion to depict the area at risk (AAR) [3]. All pigs were 
scheduled to undergo two CMR exams, at 7 and 45 days 
after infarction induction. Animals in each ischemia time 
group were randomly allocated to i.v. metoprolol (0.75 mg/
kg of 1 mg/ml Beloken®, Casen Recordati, Italy) [7] or i.v. 
vehicle (0.75 ml/kg saline). All metoprolol and vehicle injec-
tions were at 20 min after ischemia onset. Drug or vehicle 
was administered always at 20 min after the ischemia onset, 
in order to mimic the normal delay between symptoms and 
medical assistance in clinical arena. Operators were blinded 
to treatment allocation. The sample size of pigs scheduled 
to 40 min, 45 min, and 50-min I/R was N = 12 per group, 
whereas sample size for the 20-min, 25-min, 30-min, 
35-min, and 60-min I/R groups was N = 5 per group. Dead 
animals were not replaced. All animals (including those allo-
cated to vehicle during ischemia) received 50 mg daily oral 
metoprolol throughout the study, starting the day after I/R 
induction. Clopidogrel (150 mg) was administered imme-
diately after reperfusion, followed by 75 mg daily for two 
additional days.
The pre-specified primary endpoint IS [extent of late gad-
olinium enhancement (LGE) normalized to AAR] on day 7 
CMR. Secondary outcomes were microvascular obstruction 
(MVO) on day 7 CMR as well as left ventricular (LV) vol-
umes and LV systolic function (LV ejection fraction, LVEF) 
on day 45. For comparative purposes, hemodynamic param-
eters (systolic and diastolic blood pressure) before ischemia 
onset and upon reperfusion, incidence and timing of ven-
tricular fibrillation (VF) events, and mortality were recorded 
in all animals throughout the study.
Pig model of STEMI (ischemia–reperfusion (I/R) 
protocol)
The MI-induction protocol is detailed elsewhere [5, 32]. In 
brief, sedation was induced by intramuscular injection of 
ketamine (20 mg/kg), xylazine (2 mg/kg), and midazolam 
(0.5 mg/kg) and maintained by continuous intravenous infu-
sion of ketamine (2 mg/kg/h), xylazine (0.2 mg/kg/h), and 
midazolam (0.2 mg/kg/h). The analgesic buprenorphine 
(0.03 mg/kg) was administered by intramuscular injection 
immediately before the procedure. Animals were intubated 
and received mechanical ventilatory support with manda-
tory synchronized intermittent volume-control ventilation 
(fraction of inspired  O2, 28%). Central venous and arterial 
lines were inserted, and a single bolus of unfractionated 
heparin (300 IU/kg) was administered at the onset of the 
instrumentation. During the procedure, animals were con-
tinuously infused with amiodarone (300 mg/h). Amiodarone 
was initiated immediately after coronary artery occlusion. 
Through the femoral arterial sheath, a guiding catheter was 
placed in the left main coronary artery. A coronary wire was 
placed distal in the LAD, and an angioplasty balloon was 
inflated in the mid-LAD, occluding the LAD immediately 
distal to the origin of the first diagonal branch. Balloon loca-
tion, maintenance of inflation, and post-reperfusion patency 
were monitored by contrast angiography. In cases of VF, 
non-synchronized biphasic defibrillations were applied until 
sinus rhythm was restored.
Arterial enhanced MDCT protocol and AAR 
quantification
After coronary artery occlusion, pigs were moved to the 
MDCT suite. In all cases, pigs were back in the catheteri-
zation laboratory within 15 min of ischemia onset. Arte-
rial phase MDCT studies were performed in a 64-slice CT 
scanner (Brilliance CT 64; Philips Healthcare, Cleveland, 
OH) after intravenous administration of iodinated contrast 
medium. MDCT images were evaluated with dedicated soft-
ware (MR Extended Work Space 2.6; Philips Healthcare, 
Best, The Netherlands) by two observers blinded to ischemia 
duration protocol and treatment allocation. Short-axis orien-
tation images were obtained from volumetric CT images by 
multiplanar reconstruction. The region negative for contrast 
enhancement corresponds to the territory supplied by the 
occluded vessel (AAR) and was identified based on contrast 
enhancement differences vs the remote myocardium. The 
AAR was manually delineated and expressed as a percent-
age of LV area.
CMR protocol and analysis
Cine and contrast-enhanced CMR studies were performed 
7 days and 45 days after MI induction. CMR examinations 
were conducted using a Philips 3-T Achieva Tx whole 
body scanner (Philips Healthcare, Best, The Netherlands) 
equipped with a 32-element phased-array cardiac coil. 
The imaging protocol included a standard segmented cine 
steady-state free-precession sequence to provide high-quality 
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anatomic references and assessment of LV volumes, LV 
mass, and LVEF, as well as a T1-weighted inversion recov-
ery turbo field echo sequence acquired 10–15 min after the 
administration of gadolinium contrast to assess IS (extent 
of LGE) and MVO (dark regions within the LGE region). 
CMR images were evaluated with dedicated software (MR 
Extended Work Space 2.6; QMassMR 7.6; Medis, Leiden, 
The Netherlands) by 2 observers experienced in CMR analy-
sis and blinded to group allocation.
Statistical analysis
Sample size was calculated according to previous results, for 
a power 80%, significance level of 5% and expected mortal-
ity of 30%.
Categorical variables are expressed as percentages and 
were compared by the chi-square test (or the Fisher exact 
test when appropriate). Normal distribution of each data 
subset was checked using graphical methods and a Sha-
piro–Wilk test. Continuous variables are expressed as 
mean ± standard deviation if normally distributed and other-
wise as median (interquartile range [IQR]). Between-group 
comparisons were made by parametric methods (nonpaired 
Student’s t test) or nonparametric methods (Mann–Whitney 
U test) as appropriate. Differences were considered statisti-
cally significant at p < 0.05 (two tailed).
Cumulative mortality was calculated using the 
Kaplan–Meier method. The difference in survival estimates 
across dipstick categories was assessed by the log-rank test.
Slopes of myocardial damage over ischemia time in the 
vehicle and metoprolol groups were adjusted using an asym-
metric sigmoidal model (least squares regression).
All statistical analyses were performed with Stata v15.1 
(StataCorp, College Station, TX). Graphs were generated 
with GraphPad-Prism v7.0 (GraphPad Software, Inc, La 
Jolla, CA).
Results
Experimental MI was induced in 122 pigs. Of these, two 
animals died during MI induction due to refractory VF (1 in 
a metoprolol group 1 in a vehicle group). A further 4 animals 
died during the week after MI induction, before complet-
ing the 7-day CMR (1 in a metoprolol group, 3 in vehicle 
groups), and 14 animals died between day 7 and day 45, thus 
only undergoing the day 7 CMR (4 in metoprolol groups, 10 
in vehicle groups). Therefore, overall mortality was 26.2% 
among vehicle-treated pigs vs. 9.8% among metoprolol-
treated pigs (p = 0.07) (Fig. 2). There were no differences 
in hemodynamic parameters across treatment allocation 
for any ischemia duration (Table 1). Of note, the incidence 
and number of VF episodes during ongoing ischemia were 
significantly lower in animals allocated to metoprolol (36.5% 
for vehicle vs. 20.8% for metoprolol; p = 0.001) (Fig. 3).
Infarct size trajectories over time in the pig 
infarction–reperfusion model
Infarct size was evaluated on day 7 CMR. Among pigs allo-
cated to vehicle, infarctions in the 20-min I/R protocol were 
very small (6.2 [0.0–9.7] % AAR). Increases in ischemia 
duration from 20 to 35  min resulted is an exponential 
increase in IS (72.7 [69.0–87.3] %AAR). An ischemia dura-
tion of 40 min resulted in a further increase in IS to occupy 
almost the entire AAR (97.8 [87.9–100.0] % AAR) (Fig. 4). 
Absolute infarct size (% LV) followed the same temporal 
progression pattern (Fig. 5).
Fig. 2  Kaplan–Meier survival curves in pigs receiving metoprolol or 
vehicle during ischemia
Table 1  Hemodynamic parameters during myocardial infarction 
induction
Data from animals in different ischemia duration protocols were 
pooled according to treatment allocation (metoprolol or vehicle)
Data are presented as mean ± standard deviation unless otherwise 
noted
Vehicle Metoprolol p value
Baseline (before myocardial infarction induction)
 Heart rate (beats per min) 76.6 ± 9.5 76.2 ± 9.9 0.860
 Systolic blood pressure (mmHg) 113.1 ± 8.0 113.5 ± 7.8 0.821
 Diastolic blood pressure 
(mmHg)
71.5 ± 5.8 69.1 ± 7.1 0.079
Post-reperfusion
 Heart rate (beats per min) 91.8 ± 9.6 90.9 ± 7.8 0.612
 Systolic blood pressure (mmHg) 88.8 ± 9.6 87.5 ± 9.9 0.498
 Diastolic blood pressure 
(mmHg)
58.8 ± 6.3 56.8 ± 6.1 0.125
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Impact of early i.v. metoprolol administration 
on infarct size trajectories
For all ischemia durations, i.v. metoprolol was injected 
20 min after ischemia onset in animals allocated to active 
treatment. In the 20 and 25-min I/R groups, IS after meto-
prolol injection at min 20 did not differ significantly from 
that in vehicle-treated pigs (Figs. 4, 5). Infarcts in animals 
injected with metoprolol at min 20 and reperfusion at 30, 35, 
40, or 50 min after ischemia onset were consistently smaller 
than in vehicle-treated counterparts (Figs. 4, 5). The protec-
tion afforded by metoprolol was lost when reperfusion was 
delayed to 60 min; pigs receiving metoprolol at min 20 and 
reperfused at 60 min had virtually the same infarct size as 
their vehicle-treated counterparts. IS trajectories in vehicle- 
and metoprolol-treated pigs are shown in Fig. 6.
Fig. 3  Incidence and timing of 
primary ventricular fibrilla-
tion. Left panel: percentage of 
animals with ventricular fibril-
lation (VF) per group (pooled 
data). The color scale ranking 
highlights the difference in VF 
incidence between pigs receiv-
ing saline and pigs receiving 
metoprolol. Right panel: plot of 
cumulative VF incidence (per-
centage of animal suffering at 
least one VF) against time from 
ischemia onset to first VF
Fig. 4  Infarct size (normalized to area at risk) according to the dura-
tion of ischemia in metoprolol and vehicle-treated pigs. Infarct size as 
% of the AAR (area at risk) at 7-day CMR follow-up in groups allo-
cated to different lengths of ischemia. Blue columns represent vehi-
cle groups; orange columns represent metoprolol groups. Pooled total 
cohorts represent animals receiving vehicle (blue) versus animals 
receiving metoprolol (orange) irrespective of ischemia duration. Data 
are presented as median and IQR. Dots represent data for individual 
animals. ns non-significant; *p < 0.05, **p < 0.01, ***p < 0.001
Fig. 5  Absolute infarct size according to duration of ischemia in 
metoprolol and vehicle-treated pigs. Infarct size as % of the left ven-
tricle at 7-day CMR follow-up in groups allocated to different lengths 
of ischemia. Blue columns represent vehicle groups; orange columns 
represent metoprolol groups. Pooled total cohorts represent animals 
receiving vehicle (blue) versus animals receiving metoprolol (orange) 
irrespective of ischemia duration. Data are presented as median and 
IQR. Dots represent data for individual animals. ns non-significant; 
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. LV left ventricle
Fig. 6  Time-dependent progression of infarct size in the presence or 
absence of metoprolol. Slope progression of infarct size (% AAR) 
with time of ischemia (minutes). Blue, vehicle group; orange, meto-
prolol group. Data are presented means (dots) ± SD (lines)
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Pooling of data from all ischemia duration protocols 
revealed that pigs receiving i.v. metoprolol had significantly 
smaller relative infarctions (% AAR) (Fig. 4) and absolute 
infarctions (% LV) than those injected with vehicle (Fig. 5).
Attenuation of infarct size progression by early i.v. 
metoprolol administration
To evaluate the ischemic injury attenuation induced by early 
i.v. metoprolol injection in the course of an infarction, we 
compared IS in pigs undergoing 50-min I/R in the presence 
of metoprolol vs. those undergoing shorter I/R protocols 
without metoprolol. Infarct size (%AAR) in pigs undergoing 
50-min I/R and injected i.v. with metoprolol at ischemia min 
20 had significantly smaller infarctions than vehicle-treated 
pigs undergoing 40 and 45-min I/R protocols. IS (%AAR) in 
metoprolol-treated pigs undergoing 50-min I/R did not differ 
from that in control pigs undergoing 35-min I/R (Fig. 7).
Impact of early i.v. metoprolol administration 
on left ventricular ejection fraction 
and microvascular obstruction
Long-term (day 45) LVEF was higher in metoprolol-treated 
pigs in all ischemia duration protocols, although statistical 
significance was reached only in the 35- and 40-min I/R 
groups. Pooling of data from all ischemia duration protocols 
revealed that pigs receiving i.v. metoprolol had significantly 
higher long-term LVEF than those injected with vehicle 
(Fig. 8). MVO g) on day 7 CMR did not differ between 
vehicle- and metoprolol-treated pigs. All CMR parameters 
on day 7 and day 45 are shown for all ischemia duration 
protocols in Table 2.
Discussion
In the present study, we used a translational pig I/R model 
to determine the trajectories of infarct size progression in 
control conditions and in the presence of i.v. metoprolol 
delivered 20 min after ischemia onset. Reperfusion was ini-
tiated at different timings after ischemia onset, ranging from 
20 min (immediately after vehicle/metoprolol injection) to 
60 min (40 min after vehicle/metoprolol injection). CMR 
was performed on day 7 to quantify the extent of irrevers-
ible injury and on day 45 to measure long-term LVEF. The 
principal finding of the present study is that i.v. metoprolol 
significantly delays infarction progression (Fig. 6). These 
data identify i.v. metoprolol as one of the few interventions 
that can be initiated after ischemia onset able to reduce the 
progression of irreversible injury. To date, only reperfusion 
itself [28], and remote ischemic per-conditioning [24], were 
demonstrated to have this anti-ischemic damaging effect.
In STEMI survivors, the extent of irreversible injury 
(myocardial IS) is a strong predictor of long-term adverse 
events [20, 35]. Consequently, the extent of CMR-LGE (a 
surrogate for IS) is recommended as the primary outcome in 
clinical trials and large animal studies addressing the effect 
of cardioprotective strategies during STEMI [19]. Due to 
their independent association with outcomes, LVEF and 
MVO are also recommended as secondary outcomes [19]. 
Fig. 7  Early administration of metoprolol delays infarct progression. 
Differences in IS (% AAR) between animals receiving i.v. metoprolol 
and 50  min of ischemia and animals receiving i.v. vehicle and 35-, 
40-, or 45-min ischemia. ns non-significant; *p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001
Fig. 8  Long-term left ventricular ejection fraction according to dura-
tion of ischemia in metoprolol and vehicle-treated pigs. LVEF at 
45-day CMR follow-up in groups allocated to different lengths of 
ischemia. Blue, vehicle groups; orange, metoprolol groups. Pooled 
total cohorts represent animals receiving vehicle (blue) versus ani-
mals receiving metoprolol (orange) irrespective of ischemia duration. 
Data are presented as Median and IQR. Dots represent data for indi-
vidual animals. ns non-significant; *p < 0.05, **p < 0.01
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In the present study, we measured these three outcomes to 
evaluate the impact of metoprolol on irreversible myocardial 
damage. The beneficial effect of i.v. metoprolol injected dur-
ing ischemia on all three surrogate markers strongly supports 
the potential of this intervention. It should be noted that 
despite metoprolol reduced MVO in some ischemia duration 
protocols, the incidence of this event was low in all prepara-
tions. It is well known that MVO is very frequent in different 
I/R models, including patients [12].
Classical studies using a large animal model of MI dem-
onstrated that IS increases with time [28]. Other variables 
influencing the rate of irreversible injury progression include 
temperature and the presence of collaterals. Time-dependent 
IS progression was originally demonstrated in the dog [28], 
whose well-developed net of collaterals slows IS progres-
sion. Due to its anatomical and physiological similarities 
to humans, the large white pig is the most widely used I/R 
model [19]. Pigs lack collaterals, and IS progression is thus 
faster than in dogs. Our data show that most of the area 
subtended to ischemia becomes irreversibly injured between 
20 and 35 min after ischemia onset. These data have impor-
tant implications for future studies using this model because 
they show that, in the absence of strategies to alter ischemic 
injury, there is a very narrow time-window for reducing 
IS. Fast IS progression in humans usually occurs in young 
patients with no pre-existing collaterals, in whom large 
infarctions can be observed despite moderate ischemia dura-
tions [2]. This population is at much higher risk than older 
patients, who better tolerate prolonged ischemia. Time-
dependent IS progression is generally slower in the clinical 
setting than in the pig model used here, with IS progres-
sion taking at least 2 h to occupy most of the AAR [8]. We, 
therefore, hypothesize that the timing of metoprolol injection 
in our study (20 min after ischemia onset, or half the time 
taken for IS to represent most of the AAR in the pig) might 
be comparable to the clinical setting of a patient presenting 
during the first hour of STEMI (half the time taken for IS to 
represent most of the AAR in humans).
Interventions able to reduce IS beyond the effect of reper-
fusion itself would have major prognostic implications, and 
as such their identification is an unmet clinical need [21]. 
In the past, most tested interventions have targeted reper-
fusion injury, under the premise that this form of damage 
significantly contributes to final IS [13, 15]. Unfortunately, 
most clinical trials of these interventions have failed to dem-
onstrate a clinical benefit [10, 16, 36]. There is, therefore, 
renewed interest in identifying strategies able to delay the 
IS progression (ischemic injury) [31]. In the present study, 
we show that metoprolol significantly attenuates the time-
dependent progression of IS (Fig. 6), thus positioning this 
strategy as one of few able to improve long-term outcomes 
in STEMI patients when applied in conjunction with reper-
fusion. Another intervention that has been shown to reduce 
ischemic injury is remote ischemic pre-conditioning. Klein-
bongard et al. recently demonstrated in a similar pig model 
of reperfused MI that remote ischemic conditioning initi-
ated after coronary occlusion resulted in attenuation of ST-
segment elevation despite ongoing coronary occlusion and 
this translated into smaller MI size [24]. These data strongly 
suggest that this intervention attenuated ischemic injury. In 
the clinical setting, remote ischemic per-conditioning has 
recently failed to improve clinical outcomes in STEMI 
patients [11]. However, it should be noted that patients 
enrolled in this trial in many centers were enrolled in the 
cath lab, and the time from conditioning onset to reperfusion 
was very short many times, leaving a very small room for 
ischemia progression attenuation.
The infarct-limiting effects of metoprolol in STEMI 
patients undergoing PPCI have been tested in two rand-
omized clinical trials (the METOCARD-CNIC [22, 27] and 
the EARLY-BAMI trials [29]), which produced different 
outcomes [26]. In the METOCARD-CNIC trial, metopro-
lol administration was associated with smaller infarcts [22] 
and higher long-term LVEF [27], whereas in the EARLY-
BAMI study, metoprolol did not improve clinical outcomes 
[29]. In both trials, metoprolol was shown to be safe and to 
reduce the incidence of primary VF. An important difference 
between the trials is the timing of metoprolol administration. 
In METOCARD-CNIC, metoprolol was injected immedi-
ately after STEMI diagnosis, whereas in the EARLY-BAMI 
trial, some patients did not receive the full metoprolol dose, 
or received it when they reached the catheterization lab [26]. 
Our results reconcile the apparent contradictory trial find-
ings and confirm that metoprolol most likely exerts its cardi-
oprotective effect by slowing IS progression. Metoprolol is a 
potent protector against reperfusion injury in mouse models 
of I/R [6]; however, reperfusion injury appears to contribute 
less to final IS in pigs and humans than in rodents, and this 
difference might partially explain the failures to translate 
promising cardioprotective strategies to the clinic. In this 
regard, it has been proposed that there is a narrow ischemia 
duration window at which reperfusion-related injury signifi-
cantly contributes to IS in large animals and humans [14]. 
If this was the case, part of the benefits of metoprolol seen 
in our study could have also been the result of reperfusion-
injury amelioration, which was seen at ischemia duration 
protocols of 30–50 min, neither shorter nor longer than this 
window. In this regard, we previously demonstrated that part 
of the metoprolol-related infarct-limiting effects was driven 
by a direct effect on neutrophils and neutrophil–platelet 
interactions, reducing reperfusion-related injury [6]. If this 
was also a prevailing mechanism in the large animal model, 
it might be very well the case that to induce neutrophil stun-
ning in a significant number of cells, metoprolol needs a 
time of circulation. This could partially explain the benefits 
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observed only when metoprolol was on board 10 min or 
more.
One aspect than deserves explanation is the lack of differ-
ences between metoprolol and vehicle in terms of heart rate 
or blood pressure at reperfusion. Metoprolol has a known 
hemodynamic effect not observed in our experimental set-
ting. The reason for this is the use of continuous amiodarone 
infusion (300 mg/h) in both treatment groups. Amiodarone 
has strong effects on heart rate and blood pressure. It is note-
worthy that even in the absence of differences in heart rate, 
metoprolol administration was associated with significant 
IS-reducing effect. These data clearly dissociate the heart 
rate reducing effect to the cardioprotective one and explain 
why other drugs that lower heart rate, such as calcium chan-
nel blockers, are not associated with IS-reducing effect.
Reperfusion (either mechanical by PPCI or pharmaco-
logical by fibrinolysis) has become the mainstay treatment 
for STEMI patients. Head-to-head comparison of these 
approaches clearly favors PPCI, which results in a more 
complete reperfusion with less MVO and is associated with 
fewer complications. However, PPCI is not always an imme-
diate option, and triaging patients for PPCI delays reperfu-
sion. Current guidelines recommend transfer of patients to 
the PPCI center over immediate fibrinolysis so long as this 
can be done within 120 min of STEMI diagnosis [21]. The 
significant slowing of IS progression afforded by metoprolol 
could be especially beneficial for patients facing a long jour-
ney time to the PPCI center. Early administration of meto-
prolol, especially to patients presenting anterior infarctions, 
early in the course of STEMI (within 1–2 h from symptom 
onset), might extend the time window for selecting PPCI 
over fibrinolysis, thus allowing the best reperfusion strat-
egy to be offered to patients who otherwise would receive 
fibrinolysis. As a limitation to this hypothesis the effects of 
metoprolol added to fibrinolytic therapy is unknown.
An additional benefit of metoprolol is the reduction in 
VF, shown here and in previous clinical trials [26]. In this 
regard, it has been shown in the pig model of reperfused MI 
that the incidence of VF (not the number of events or defi-
brillations) is associated with larger IS [34]. Skyschally et al. 
showed that VF is associated with larger AAR and lower 
residual myocardial blood flow [34]. Given that in our study 
AAR was not different between groups, it is highly plausible 
that metoprolol had an impact on residual blood myocardial 
flow and this resulted in a reduced incidence of VF, as well 
as in a reduction of the ischemic injury progression. Clinical 
practice guidelines indicate i.v. beta-blockers upon STEMI 
diagnosis with a class of recommendation IIa and level of 
evidence A [21]. However, this recommendation is rarely 
implemented [9]. This seems a lost opportunity for STEMI 
patients given the strong attenuation of time-dependent IS 
progression shown here for metoprolol, plus its safety when 
administered to stable patients (Killip class I–II) and its 
potency in reducing primary VF [22, 29]. What is needed 
is a definitive randomized clinical trial enrolling patients 
presenting far from the PPCI center (e.g. at the limit of the 
120 min delay) to demonstrate the clinical benefits of early 
i.v. metoprolol administration and thus convince the clinical 
community of the value of this therapeutic strategy.
Limitations
Our conclusions are limited by the use of the pig model. 
Pigs are widely used as a translational model because of the 
similarities of their hemodynamic parameters and heart and 
coronary anatomy to humans [4, 19]. However, the pig heart 
has poor collateral flow, and this lack of collaterals may 
translate into a faster progression of myocardial damage than 
occurs in patients. Other potential limitation is referred to 
VF, interactions between metoprolol and amiodarone could 
affect this anti-arrhythmic effects.
Conclusions
Using a pig model of reperfused STEMI, we have shown 
that early i.v. injection of metoprolol is able to delay the 
time-dependent progression of irreversible myocardial dam-
age. IS in pigs receiving metoprolol at 20-min ischemia and 
reperfused at 50 min was equal to that of vehicle-treated pigs 
undergoing ischemia for 35 min (30% less ischemia time) 
and significantly smaller than vehicle-treated pigs reperfused 
at 40 min. Early i.v. metoprolol injection in the course of 
experimental MI results in better long-term LVEF. Metopro-
lol significantly reduced the incidence of primary VF dur-
ing ischemia and long-term mortality. Early i.v. metoprolol 
administration seems best suited for patients presenting early 
in the course of STEMI with a long anticipated transport 
time to the PPCI center.
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